Clinical TrialsSearch results
Number of results: 215
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- [M23-784] A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
- Crohn's Disease
- Otani Tetsuya
- 2024-03-11
Recruiting
- A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 18 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids
- Dermatitis atopic
- Tanaka Tomoyuki
- 2024-01-13
Recruiting
- A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 18 years and older with moderate-to-severe atopic dermatitis
- Dermatitis atopic
- Tanaka Tomoyuki
- 2024-01-13
Recruiting
- A study to evaluate efficacy and safety of SAR441566 in adults with plaque psoriasis
- Psoriasis
- Tanaka Tomoyuki
- 2024-01-09
Recruiting
- Exploratory Study on the Efficacy of "Boosted CT Myelography"
- cerebrospinal fluid hypovolemia
- Eiichi Nakai
- 2023-11-13
Recruiting
- Relationship between sedative drugs and EEG
- general anesthesia
- Iwata Hideki
- 2023-08-23
Recruiting
- A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- Hidradenitis Suppurativa
- Yamazaki Hayato
- 2023-06-27
Recruiting
- A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
- Ulcerative colitis or Crohn's Disease
- Kashiyama Akinori
- 2023-04-11
Recruiting
- Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis
- Dermatitis atopic
- Tanaka Tomoyuki
- 2023-03-20
Completed
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease
- Pneumococcal infection prevention
- Tanaka Yoshiyuki
- 2023-03-03